| A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants NCT07413367 | Fase 1 | En marcha, sin reclutar |
| Trastorno depresivo mayor, Depresión NCT07621237 | Fase 2 | Reclutando pacientes |
| Fibromialgia NCT05273749 | Fase 3 | Completado |
| COVID-19 NCT05472090 | Fase 2 | Completado |
| Trastorno de estrés postraumático NCT05372887 | Fase 2 | Retirado antes de empezar |
| A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects NCT07464535 | Fase 1 | Completado |
| Fibromialgia NCT04508621 | Fase 3 | Completado |
| Fibromialgia NCT04172831 | Fase 3 | Completado |
| Trastorno de estrés postraumático NCT03841773 | Fase 3 | Interrumpido |
| Dose-Proportionality and Food Effect Study of TNX-102 SL NCT04164719 | Fase 1 | Completado |
| Trastorno de estrés postraumático NCT03508700 | Fase 3 | Completado |
| Trastorno de estrés postraumático NCT03062540 | Fase 3 | Interrumpido |
| Trastorno de estrés postraumático NCT03110575 | Fase 3 | Interrumpido |
| Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules NCT03443960 | Fase 1 | Completado |
| A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients NCT02589275 | Fase 3 | Completado |
| Fibromialgia, Enfermedades del sistema nervioso NCT02829814 | Fase 3 | Interrumpido |
| Fibromialgia, Enfermedades del sistema nervioso NCT02436096 | Fase 3 | Completado |
| Trastorno de estrés postraumático NCT02421679 | Fase 2 | Completado |
| Trastorno de estrés postraumático NCT02277704 | Fase 2 | Completado |
| BESTFIT-OLE NCT02015234 | Fase 3 | Completado |
| BESTFIT NCT01903265 | Fase 2/3 | Completado |
| Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults NCT01889173 | Fase 1 | Completado |